Envestnet Asset Management Inc. Acquires 155,537 Shares of Danaher Corporation (NYSE:DHR)

Envestnet Asset Management Inc. grew its position in Danaher Corporation (NYSE:DHR - Free Report) by 14.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,261,196 shares of the conglomerate's stock after purchasing an additional 155,537 shares during the period. Envestnet Asset Management Inc. owned approximately 0.18% of Danaher worth $258,545,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Fortis Capital Advisors LLC lifted its holdings in shares of Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after purchasing an additional 50 shares in the last quarter. Fayez Sarofim & Co raised its holdings in Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC raised its holdings in Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after acquiring an additional 50 shares in the last quarter. Perennial Investment Advisors LLC raised its holdings in Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after acquiring an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its holdings in Danaher by 3.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after acquiring an additional 52 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock traded down $0.45 on Friday, hitting $205.06. The stock had a trading volume of 383,117 shares, compared to its average volume of 3,493,985. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The business's 50 day moving average is $195.94 and its two-hundred day moving average is $206.65. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The stock has a market cap of $146.75 billion, a price-to-earnings ratio of 39.80, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. Analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Insider Activity at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank Of Canada reiterated an "outperform" rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. TD Cowen upped their target price on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Jefferies Financial Group dropped their target price on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. JPMorgan Chase & Co. dropped their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Finally, UBS Group dropped their target price on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $248.43.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.